• BMSC Exosomal Egr2 Modulates Neuronal Injury via RNF8/DAPK1

  2026-05-18

  This study uncovers how bone marrow-derived mesenchymal stem cell (BMSC) exosomal Egr2 protects neurons from ischemic injury by orchestrating the RNF8/DAPK1 signaling axis. The findings clarify a novel mechanism of neuroprotection relevant for stroke research and highlight advanced co-immunoprecipitation approaches for validating protein-protein interactions.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Techn

  2026-05-18

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) provides broad-spectrum protection against proteolytic degradation during protein extraction, especially where divalent cation preservation is required. It is not suitable for workflows dependent on EDTA-mediated metalloprotease inhibition or in cases where DMSO sensitivity is an issue.

• Senolytic Sensitivity in Melanoma: Insights from Combination

  2026-05-17

  This study systematically characterizes how human melanoma cells with diverse mutational backgrounds respond to senescence-inducing treatments and explores the selective vulnerability of therapy-induced senescent cells to Bcl-2/Bcl-xL inhibitors like Navitoclax. The findings clarify the context-dependent efficacy of senolytics and offer guidance for designing combinatorial strategies to overcome resistance in melanoma.

• Applied Workflows with the One-step TUNEL Cy3 Apoptosis Dete

  2026-05-16

  Unlock rapid, sensitive apoptosis quantification in diverse models using the One-step TUNEL Cy3 Apoptosis Detection Kit. This guide delivers advanced protocols, troubleshooting, and insights drawn from recent breakthroughs in apoptosis research and liver injury models.

• Metabolic Reprogramming in Posterior Fossa Malignancies: Bey

  2026-05-15

  This dissertation advances our understanding of metabolic alterations in posterior fossa malignancies, moving beyond classical Warburg metabolism. By integrating phosphoproteomic and metabolic profiling, the study illuminates novel regulatory patterns in tumor biology with significant implications for therapeutic targeting and experimental workflow optimization.

• Polymer Chirality Modulates IR-1061 Encapsulation for Deep N

  2026-05-15

  This study investigates how the chiral structure of hydrophobic polymers influences the encapsulation and fluorescence behavior of the near infrared fluorescent dye IR-1061 for deep tissue imaging. By comparing poly(lactic acid) enantiomers, the research reveals critical structure-affinity relationships that inform the design of highly emissive fluorescent probes for biomedical applications.

• Asunaprevir (BMS-650032): Molecular Insights and Translation

  2026-05-14

  Explore Asunaprevir (BMS-650032) as a potent HCV NS3 protease inhibitor, uncovering its molecular mechanism, translational potential, and practical assay considerations for hepatitis C research. This in-depth analysis delivers unique scientific perspectives and actionable protocols for antiviral discovery.

• Forsythoside E: PKM2 Inhibitor for Macrophage M2 Polarizatio

  2026-05-14

  Forsythoside E combines precise PKM2 inhibition with robust promotion of macrophage M2 polarization, enabling targeted metabolic reprogramming in sepsis-induced liver injury and inflammation studies. Its well-defined binding kinetics, reproducible dosing, and compatibility with advanced immunometabolic assays set a new benchmark for translational research.

• One-step TUNEL Cy3 Apoptosis Detection Kit: Applied Workflow

  2026-05-13

  The One-step TUNEL Cy3 Apoptosis Detection Kit streamlines sensitive DNA fragmentation analysis in both tissue sections and cultured cells, empowering high-confidence apoptosis detection across diverse research models. This guide delivers actionable insights on protocol optimization, advanced use-cases, and troubleshooting strategies to maximize signal fidelity and experimental reproducibility.

• Proteasome Inhibition Redefined: Strategic Insight for Trans

  2026-05-13

  Explore how Clasto-Lactacystin β-lactone, a potent and irreversible proteasome inhibitor, empowers translational researchers to dissect the ubiquitin-proteasome pathway in inflammation, cancer, and viral pathogenesis. This thought-leadership article blends mechanistic insight, experimental strategy, and cross-domain translational relevance—moving beyond conventional product summaries and illuminating new research frontiers.

• Nuclear Export Inhibition Combinations in Basal-like TNBC Mo

  2026-05-12

  This study systematically identifies and validates combination therapies incorporating nuclear export inhibition for basal-like triple-negative breast cancer (TNBC). Using preclinical models, KPT-330 (Selinexor) paired with a PI3K/mTOR inhibitor demonstrated synergistic tumor suppression, highlighting a promising targeted approach for this aggressive cancer subtype.

• Berberrubine Mitigates Hyperuricemia via Urate Transporter a

  2026-05-12

  This study demonstrates that berberrubine, a metabolite of berberine, robustly reduces hyperuricemia in mouse models by modulating renal urate transporters and suppressing the JAK2/STAT3 signaling pathway. These findings highlight berberrubine's mechanism-based potential for developing targeted therapies for hyperuricemia and associated renal inflammation.

• LG 101506: RXR Modulator-Driven Assay Design in Immunometabo

  2026-05-11

  Explore how LG 101506, a synthetic RXR modulator, is redefining experimental strategies in RXR signaling pathway research and immunometabolic assay design. This article delivers unique, evidence-based guidance for advanced applications and decision-making in nuclear receptor biology.

• M344 HDAC Inhibitor Suppresses Neuroblastoma Tumor Growth

  2026-05-11

  This study demonstrates that M344, a potent histone deacetylase inhibitor, exerts superior cytostatic and cytotoxic effects in neuroblastoma models compared to established HDAC inhibitors. The work elucidates M344’s mechanistic impact on tumor growth, cell cycle arrest, and apoptosis, supporting its promise as an epigenetic therapeutic in pediatric oncology.

• SN-38 and Camptothecin Disrupt FUBP1–FUSE Binding in Cancer

  2026-05-10

  This study uncovers that camptothecin and its active metabolite SN-38, beyond inhibiting DNA topoisomerase I, directly interfere with the interaction between the oncoprotein FUBP1 and its DNA target sequence FUSE. These findings introduce a dual-inhibition mechanism with implications for advanced colon and liver cancer research, offering expanded molecular targets for therapeutic investigation.

448 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page